Trials / Completed
CompletedNCT01289015
Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 855 (actual)
- Sponsor
- Merz North America, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of NAFT-600, applied once daily for 2 weeks, when compared to placebo for 2 weeks in the treatment of subjects with tinea pedis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NAFT-600 ( naftin 2 % gel ) | Topical; applied once daily for two weeks |
| DRUG | Placebo | Topical; applied once daily for two weeks |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-11-01
- Completion
- 2012-01-01
- First posted
- 2011-02-03
- Last updated
- 2013-09-26
- Results posted
- 2013-09-26
Locations
23 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT01289015. Inclusion in this directory is not an endorsement.